VTX-2337-HN-001: a neoadjuvant combination immunotherapy trial opens at Boston Medical Center

October 21, 2020

VTX-2337-HN-001 A Phase 1b Multicenter Pre-Surgical Study to Evaluate Immune Biomarker Modulation in Response to Motolimod (VTX-2337) in Combination with Nivolumab in Subjects with Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN) will be activated this week at Boston Medical Center. The study is open to patients with a new diagnosis of head and neck squamous cell carcinoma who will be undergoing surgical treatment. In this study, patients will receive either an immune checkpoint inhibitor (Nivolumab), a selective Toll-like Receptor 8 (TLR8) agonist or a combination, prior to surgery. The Faden Lab will conduct immunogenomic correlate studies from tissue biopsies to study how these drugs impact the tumor immune microenvironment. This work will be done in collaboration with the Stott Lab (MGH) and Sade-Feldman Lab (MGH).